Literature DB >> 2242678

Orthopoxvirus genetics.

R C Condit1, E G Niles.   

Abstract

Genetic analysis of orthopoxviruses has contributed substantially to our understanding of the functional organization of the poxvirus genome, and individual mutants provide invaluable tools for future studies of poxvirus biology. Deletion and transposition mutants, localized primarily in the termini of the genome, may be particularly useful for studying virus host range and pathogenicity. Numerous drug resistant and dependent mutants provide keys to understanding a wide variety of virus genes. A large number of well-characterized ts mutants, clustered in the center of the virus genome, are taking on an increasingly important role in research on the function of essential poxvirus genes. Genetic characterization of orthopoxviruses has progressed rapidly during the past decade, and one can reasonably anticipate a time when mutants will be available for the study of any poxvirus gene. Considerable progress toward this goal can be achieved through organized attempts to integrate and further characterize existing mutant collections and through the continued isolation and characterization of deletion, drug resistant, and ts mutants using established techniques. The most exciting possibility is that soon techniques will be available for directed mutagenesis to conditional lethality of any essential poxvirus gene.

Mesh:

Year:  1990        PMID: 2242678     DOI: 10.1007/978-3-642-75605-4_1

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  19 in total

1.  The A20R protein is a stoichiometric component of the processive form of vaccinia virus DNA polymerase.

Authors:  N Klemperer; W McDonald; K Boyle; B Unger; P Traktman
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Clustered charge-to-alanine mutagenesis of the vaccinia virus A20 gene: temperature-sensitive mutants have a DNA-minus phenotype and are defective in the production of processive DNA polymerase activity.

Authors:  A Punjabi; K Boyle; J DeMasi; O Grubisha; B Unger; M Khanna; P Traktman
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Role of vaccinia virus A20R protein in DNA replication: construction and characterization of temperature-sensitive mutants.

Authors:  K Ishii; B Moss
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  IPTG-dependent vaccinia virus: identification of a virus protein enabling virion envelopment by Golgi membrane and egress.

Authors:  J F Rodriguez; G L Smith
Journal:  Nucleic Acids Res       Date:  1990-09-25       Impact factor: 16.971

5.  Marker rescue mapping of the combined Condit/Dales collection of temperature-sensitive vaccinia virus mutants.

Authors:  Sayuri E M Kato; Nissin Moussatche; Susan M D'Costa; Travis W Bainbridge; Cindy Prins; Audra L Strahl; Amber N Shatzer; Alyson J Brinker; Nicole E Kay; Richard C Condit
Journal:  Virology       Date:  2008-03-07       Impact factor: 3.616

6.  In vitro resolution of poxvirus replicative intermediates into linear minichromosomes with hairpin termini by a virally induced Holliday junction endonuclease.

Authors:  D Stuart; K Ellison; K Graham; G McFadden
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

7.  Characterization of vaccinia virus DNA replication mutants with lesions in the D5 gene.

Authors:  E Evans; P Traktman
Journal:  Chromosoma       Date:  1992       Impact factor: 4.316

8.  Targeted construction of temperature-sensitive mutations in vaccinia virus by replacing clustered charged residues with alanine.

Authors:  D E Hassett; R C Condit
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  Vaccinia virus gene A18R encodes an essential DNA helicase.

Authors:  D A Simpson; R C Condit
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

10.  Effect of marker distance and orientation on recombinant formation in poxvirus-infected cells.

Authors:  R J Parks; D H Evans
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.